Abstract: The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

Abstract: The present invention relates to methods and kits for identifying effector regulatory T cells. In particular the present invention relates to use of CD15s as a biomarker for eTreg cells. The present invention also relates to a method for identifying effector Treg cells (eTreg) in a fluid sample comprising the steps of i) detecting the cell surface expression of CD4, CD25, CD127 and CD15s markers on the cell population contained in the fluid sample and ii) concluding that the cells expressing CD4, CD25, CD127 at low levels and CD15s are the effector Treg cells. The present invention also relates to a method for identifying effector Treg cells (eTreg) in a tissue sample comprising the steps of i) detecting the cell expression of CD4, CD25, Foxp3 and CD15s markers and ii) concluding that the cells expressing CD4, CD25, Foxp3 and CD15s are the effector Treg cells.

Abstract: The invention relates to a method for automatically processing at least one image slice of a given part of at least one lung of a patient suffering from a pathology that causes a bronchial infection by diffuse dilatation of the bronchial tubes of the lungs, the method comprising steps of segmenting (102) the at least one image slice of the given part of the lung, in order to produce a histogram characterising the pulmonary density of the given part of the lunch, by means of the voxels of the at least one image slice, each voxel being assocaited with a given pulmonary density; calculating (104) a threshold, from the histogram, corresponding to a threshold pulmonary density, based on at least one characteristic of the histogram, a first characteristic being the mode of the histogram; determining (106) from the at least one image slice of the given part of the lung, a pulmonary volume having a pulmonnar density higher or lower than the calculatedd threshold, corresponding to the sum of the voxels having a pulmon

Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: The present invention relates to a method for treating MI or AMI in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an agent capable of depleting CD8 T cells. More particularly, this present invention relates to a method for treating acute myocardial infarction by reducing the size of necrosis and limiting 10 the post ischemic left ventricular remodeling.

Abstract: A method for generating an indicator or biomarker of colour perception in a mammalian subject, where the method may include submitting the mammalian subject to a multicoloured dynamic stimulus comprising displaying, on a display device. The method may include controlling a change over time of at least one of the two colours of the multicolour pattern when displaying the dynamic multicolour stimulus, to vary the displayed luminance of this colour (usually several times). The method may include acquiring, by using an image acquisition device, an oscillatory response of a pupil of the mammalian subject. The method may include generating, from the acquired response, a signal representative of the power of the pupil's oscillatory response as a function of the change over time of at least one of the two colours when displaying the dynamic multicoloured stimulus.

Abstract: The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.

Abstract: The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said compounds, and to the pharmaceutical compositions containing same.

Abstract: The invention relates to an endovascular cutting device for carrying out surgical or medical operations. According to the invention, such a device includes two cutting blades, a means for remotely actuating the two cutting blades, and at least two flexible guide rods, said cutting blades being slidably mounted onto said guide rods, and said remote actuation means including a flexible transmission means, wherein a channel, through which the flexible guide rods (50) are to be inserted, extends through said cutting blades (11, 12, 101, 102) over the entire outer length thereof.

Abstract: The present invention relates to methods for prognosis and monitoring of a cancer, preferably bladder cancer, by measuring the proportion of CD8+ T Lymphocytes expressing ILT-2 and the plasma level of soluble HLA-G. The invention also relates to anti HLA-G antibodies for use for treating a cancer in which tumor cells express HLA-G, preferably bladder cancer.

Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.

Abstract: The invention relates to a process for determining an infiltration profile of biological cells of interest in a biological object of interest from a digital histopathological image of biological tissues, a histological stain having previously been applied to the biological tissues, comprising generating a biological cell detection image, pixels associated with the histological stain on the histopathological image being of a predetermined color on said image, determining a distance map comprising distance iso-curves to the boundary of the biological object, and, from the distance map, calculating a curve representative of the surface density of biological cells of interest as a function of distance to the boundary, by counting, for each boundary distance value, pixels that are both of the predetermined color on the detection image and located between the iso-curve associated with said distance value and the consecutive iso-curve.

Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

Abstract: An in-ear stimulation system including a first device configured to be worn at least partially in a first ear canal of a subject and a second device configured to be worn at least partially in a second ear canal of the subject. Each of the first device and the second device includes: at least one in-ear active electrode configured to receive a bio-signal and at least one in-ear reference electrode configured to receive a bio-signal; at least one stimulation device configured for emitting at least one electrical or sensory stimulus; and an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.

Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: An aerolysin nanopore or a nanotube is used for the electrical detection of peptides, proteins separated by at least one amino acid and other macromolecules such as polysaccharides or synthetic or natural polymers present in a preparation where said nanopore or nanotube is inserted into a lipid membrane which is subjected to a difference in potential greater than ?160 mV, in a reaction medium having an alkali metal halide electrolyte solution with a concentration of less than 6M and at a temperature of less than 40° C., and where said use is intended to differentiate said peptides, proteins and other molecules according to their length and their mass. Application to the sequencing of peptides and other molecules to differentiate them according to their length and mass with an amino acid-level or monomer-level resolution and to medical diagnosis.

Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.